Ranbaxy, an India-based pharmaceutical firm, produces all products in India, with costs and pricing initially stated in Indian rupees (Rp), but converted to Brazilian reais (R$) for distribution and sale in Brazil. In 2009, the unit volume was priced at Rp20,920, when the exchange rate was Rps22.9/R$. But in 2010, the real appreciated in value versus the rupee, averaging Rp26.15/R$. In order to preserve the real price (and product profit margin in rupees), what should the new rupee price be set at